Serum Lipid Profile In Patients Research Articles

Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B

BackgroundConcerns have been raised regarding changes in lipid profiles among patients with chronic hepatitis B (CHB) during tenofovir alafenamide fumarate (TAF) treatment. We aimed to evaluate the effect of TAF treatment on the lipid profiles of patients with CHB.MethodsA total of 430 patients with CHB from three hospitals were retrospectively included, including 158 patients treated with TAF and 272 patients treated with tenofovir disoproxil fumarate (TDF).ResultsIn this multicenter cohort, the cumulative incidence of dyslipidemia was notably higher in the TAF group than in the TDF group (P < 0.001). After TAF treatment, a significant elevation was observed in triglyceride (TG) levels (from 0.83 mmol/L to 1.02 mmol/L, P < 0.001) and total cholesterol (TC) levels (from 4.16 mmol/L to 4.32 mmol/L, P < 0.001). Similar changes in TG and TC levels were observed in the TAF group after propensity score matching (PSM). The TG levels (from 0.83 mmol/L to 1.04 mmol/L, P < 0.001) and TC levels (from 4.16 mmol/L to 4.38 mmol/L, P < 0.001) were both increased significantly compared to the baseline levels in the PSM cohort of patients treated with TAF. TAF treatment was independently associated with elevated TG levels (HR = 2.800, 95% CI: 1.334–5.876, P = 0.006) and TC levels (HR = 9.045, 95% CI: 3.836–21.328, P < 0.001).ConclusionsCompared with TDF treatment, TAF treatment was associated with dyslipidemia in patients with CHB. Close monitoring of lipid profiles is needed in patients with CHB who received TAF treatment.

Alterations in Serum Lipids and Lipoproteins Induced by Neoadjuvant Chemotherapy in Patients with Osteosarcoma around the Knee Joint: A Retrospective Analysis.

To investigate the serum lipid profiles of patients with localized osteosarcoma around the knee joint before and after neoadjuvant chemotherapy. After retrospectively screening the data of 742 patients between January 2007 and July 2020, 50 patients aged 13 to 39 years with Enneking stage II disease were included in the study. Serum lipid levels, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), lipoprotein-α [Lp(a)], and apolipoprotein A1, B, and E (ApoA1, ApoB, and ApoE), and clinicopathological characteristics were collected before and after neoadjuvant chemotherapy. The mean levels of TC, TG, and ApoB were significantly increased following neoadjuvant chemotherapy (16%, 38%, and 20%, respectively, vs. pretreatment values; P<0.01). The mean levels of LDL-C and ApoE were also 19% and 16% higher, respectively (P<0.05). No correlation was found between the pretreatment lipid profile and the histologic response to chemotherapy. An increase in Lp(a) was strongly correlated with the Ki-67 index (R=0.31, P=0.023). Moreover, a trend toward longer disease-free survival (DFS) was observed in patients with decreased TG and increased LDL-C following chemotherapy, although this difference was not statistically significant (P=0.23 and P=0.24, respectively). Significant elevations in serum lipids were observed after neoadjuvant chemotherapy in patients with localized osteosarcoma. There was no prognostic significance of pretreatment serum lipid levels on histologic response to neoadjuvant chemotherapy. The scale of increase in serum Lp(a) might have a potential prognostic role in osteosarcoma. Patients with increased LDL-C or reduced TG after chemotherapy seem to exhibit a trend toward favorable DFS.

Effect of Vitamin C on Blood Glucose Levels, Glycosylated Hemoglobin, and Serum Lipid Profile in Patients with Type 2 Diabetes Mellitus: A Prospective Study

Abstract Background: Vitamin C reduces oxidative stress as well as prevents nonenzymatic glycosylation of proteins because of its structural similarity to glucose. This prospective study was conducted to investigate the impact of vitamin C supplementation on glycemic control and serum lipid profile in newly diagnosed patients with type 2 diabetes mellitus (T2DM). Materials and Methods: Adult patients attending the outpatient department of a tertiary care hospital, diagnosed with T2DM within the last 3 months, with fasting blood glucose (FBG) levels exceeding 126 mg/dL, were randomly assigned to either control group (n = 98) or study group (n = 102). The study group received oral vitamin C (1 g/day) in addition to metformin 500 mg twice daily, while the control group received metformin 500 mg twice daily alone. Baseline characteristics, including age, gender, and comorbidities, were recorded. The parameters FBG, postprandial blood glucose (PPBG), glycosylated hemoglobin (HbA1c), and serum lipid profile were measured at baseline and at the 12th week. Results: Both the control and study groups experienced significant reductions in FBG, PPBG, and HbA1c levels after 12 weeks. However, the study group exhibited greater improvements, with FBG decreasing by 22.42 ± 2.7 mg/dL (P &lt; 0.05), PPBG decreasing by 33.25 ± 4.9 mg/dL (P &lt; 0.05), and HbA1c decreasing by 1.33 ± 0.3 g% (P &lt; 0.05). Additionally, both groups demonstrated significant improvements in serum lipid profile parameters, with the study group showing more significant improvements in high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol levels compared to the control group. Conclusion: Vitamin C supplementation as an adjuvant therapy with metformin for 12 weeks produces beneficial effects in T2DM patients, including improved glycemic control and significant improvement in the lipid profile.

Relationship between the complement system and serum lipid profile in patients with rheumatoid arthritis.

The complement system has been linked to the etiopathogenesis of rheumatoid arthritis (RA). Patients with RA exhibit a dysregulated profile of lipid molecules, which has been attributed to the inflammation present in the disease. In this study, we aimed to evaluate the association between a comprehensive assessment of the complement system and the lipid profile of patients with RA. 430 patients with RA were recruited. New-generation techniques were employed to conduct functional assays of the three pathways of the complement system. Serum levels of various complement components such as C1q, factor D, properdin, lectin, C1-inhibitor, C2, C4, C4b, C3, C3a, C5, C5a, and C9 were assessed. Furthermore, a complete pattern of lipid molecules was measured including high (HDL), low-density lipoproteins (LDL), and lipoprotein (a). Multivariable linear regression analysis was conducted to investigate the association between the complement system and lipid profile in RA patients. After multivariable analysis, several noteworthy associations emerged between the complement system and lipid molecules. Notably, complement components most strongly linked to the lipid profile were C1q and properdin, representing the upstream classical and alternative pathways, along with C3 from the common cascade. These associations demonstrated significance and positivity concerning total cholesterol, LDL, atherogenic index, apolipoprotein B, and lipoprotein(a), suggesting a connection with an unfavorable lipid profile. Interestingly, complement functional assays of the three pathways and activated products such as C3a and C5a showed no correlation with the lipid pattern. The correlation between the complement system and lipid molecule patterns is pronounced in patients with RA. This relationship is predominantly positive and primarily associated with upstream complement components rather than activated ones.

Exploring Serum Lipid Profile Changes in Patients During Laparoscopic Choecystectomy

Background: For quite some time, cholecystectomy has been perceived as a safe surgical procedure, often with limited attention given to potential secondary effects. It's worth noting that the gallbladder plays a significant role as a regulatory component in coordination with vital metabolic pathways responsible for maintaining equilibrium in the body. When the gallbladder is removed, bile from the liver flows directly into the upper portion of the intestine. Therefore, this study aims to evaluate the impact of laparoscopic cholecystectomy on the serum lipid profile of patients. Material and methods: A total of 60 patients diagnosed with gallstones were enrolled in this study. Preoperative blood samples were collected from all patients under sterile conditions, two hours prior to their scheduled surgery, to evaluate their lipid profile. Results: The preoperative mean Total Cholesterol (TC) levels were measured at 160.5 mg%, while postoperatively, they showed a slight decrease to 150.8 mg%. Similarly, the mean High-Density Lipoprotein Cholesterol (HDL-C) levels before surgery were 42.1 mg%, and they decreased to 40.8 mg% after the procedure. In contrast, the mean Triglyceride (TG) levels saw an increase from 180.8 mg% preoperatively to 200.8 mg% postoperatively. Notably, the comparison of mean TC and TG levels before and after the surgery yielded significant results, indicating changes in these lipid parameters following laparoscopic cholecystectomy. Conclusion: Patients undergoing laparoscopic cholecystectomy experience noteworthy changes in their serum lipid profile.

The effect of silymarin on liver enzymes and serum lipid profiles in Iranian patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial

Objectives: The aim of this study was to evaluate the effect of silymarin on liver enzyme levels and serum lipid profiles in patients with Non-Alcoholic Fatty Liver Disease (NAFLD), the most common chronic liver disease worldwide.&#x0D; Methods: This randomized double-blinded clinical trial included 80 NAFLD patients referred to the gastrointestinal clinic of Kowsar Hospital in Semnan. Forty of these patients were supplemented with 150 mg of silymarin twice a day for two months, while the other 40 received a placebo. Both groups were advised to follow a hypertriglyceridemia correction and lifestyle modification. Evaluation of serum lipid profiles and liver enzymes in both groups were performed at the baseline and after two months.&#x0D; Results: The results showed that silymarin use significantly reduced ALT (U/L) (58.72± 32.16 vs 42.2 ± 20.2, p = 0.003) and AST (U/L) (36.62± 13.46 vs 30.3 ± 9.7, p = 0.036) levels compared with the placebo group. Additionally, a statistically significant reducing effect of silymarin on triglycerides (mg/dL) (189.5 ± 65.5 vs 164.6 ± 91.3, p = 0.026), total cholesterol (mg/dL) (192.8 ± 40.3 vs 174.07± 34.5, p = 0.027), and LDL-cholesterol (mg/dL) (114.6±33.9 vs 95.6± 26.5, p = 0.012) levels was found, with no significant statistical difference for HDL-C (mg/dL) (41.5 ± 6.8 vs 43.5± 9.2, p = 0.44).&#x0D; Conclusion: Silymarin, at a dose of 150 mg twice daily, significantly reduced liver enzymes and some lipid markers in patients with NAFLD, suggesting that this compound could be a novel therapy for NAFLD.

Serum Lipid Profile in Patients with Lichen Planus

Background: Lichen planus (LP) is a chronic inflammatory disease of the skin, mucous membrane, and adnexa. There have been reports of abnormal lipid parameters being increased in patients with LP. This study evaluated the serum lipid profile in patients with LP and the control group. Materials and Methods: This case-control study was conducted in the department of Dermatology &amp; Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka. Patients with LP were taken as cases and patients with skin diseases other than LP were taken as control. Total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured by an enzymatic method. Results: This study showed higher mean TC (187 vs 168, p-value 0.01), TG (147 vs 117, p-value 0.04), LDL-C (118 vs 105, p-value 0.04) in patients with LP than control. HDL-C level shows no significant differences (38 vs 40, p-value 0.50). Odds ratio (OR) for high TC, TG &amp; LDL-C are 3.6 (95% CI: 1.26-10.56), 2.3 (95% CI: 0.87-6.31) &amp; 4.0 (95% CI: 1.4-11.6) respectively whereas OR for low HDL-C is 0.74 (95% CI: 0.31-1.77). Regarding atherogenic index, LDL-C/HDL-C and TC/HDL-C ratio was significantly higher in LP patients (p-value 0.001 &amp; 0.002 respectively). Conclusion: Analysis of lipid parameters reveals significantly higher levels of total cholesterol, triglyceride &amp; LDL-C in LP patients. The atherogenic index is also significantly higher in LP patients which is a sensitive predictor of cardiovascular risk.

Karbamazepin Kullanan Hastalarda Serum Lipid Düzeylerinin Değerlendirilmesi

Epilepsy is a neurological disease that requires long-term drug therapy. Carbamazepine (CBZ) is a drug that is effective in partial seizures, including complex partial seizures, and tonic-clonic seizures. It was aimed to evaluate the effect on serum lipid profile in patients who used CBZ. Medical biochemistry laboratory data between January and December 2021 were analyzed retrospectively. Patients (n=59) who used monotherapy and at least 2 years of CBZ were included in the study. Patients under 18 years of age were not included. In the control group, 34 healthy people with normal blood parameters, who applied to outpatient clinics for different reasons at the same age, and did not have a disease that would affect the lipid profile, were selected. The mean age of the patients was 36 ±8 years. LDL-cholesterol levels were found to be higher in patients treated with carbamazepine compared to the control group (p&amp;lt;0.05). There was no significant difference in serum triglyceride (TG), and HDL-cholesterol levels in the patient and control groups (p&amp;gt;0.05). There was no gender difference in the effect of carbamazepine on LDL-cholesterol (p&amp;gt;0.05). High serum LDL-cholesterol levels cause atherosclerosis and coronary artery disease. The lipid profile of carbamazepine, which is used regularly at the therapeutic level, changes. Due to the association of high LDL-cholesterol levels with atherosclerosis, it is important to monitor lipid levels in patients using CBZ, especially considering the long duration of use of this pharmacotherapy.

The study of serum lipid profile in patients with cirrhosis of liver

Background: Cirrhosis of liver is a chronic condition of hepatocellular failure due to different etiology which leads multiple complications and increases the morbidity and mortality. The aim of the study was to study the lipid profile in patients with cirrhosis and to assess if it relates to the severity of the cirrhosis. Hence, abnormal lipid profile may be the surrogate marker of the severity of cirrhosis of liver. Aims and Objectives: Study lipid profiles in cirrhotic patients and compare with healthy population and to relate severity of cirrhosis of liver with the finding of abnormal lipids. Materials and Methods: This study was a cross-sectional study conducted in the department of internal medicine over a period of 6 months. It was carried on 51 cirrhotic patients and 50 non-cirrhotic subjects who attended the outpatient and inpatient department. The cirrhosis of liver was established with history, examination, and investigations. Results: The mean total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very LDL (VLDL), respectively, of non-cirrhotic subjects was found to be higher than cirrhotic patients, respectively. All lipid profiles TC, TG, HDL, LDL, and VLDL value found to be (P&lt;0.05) which were statically significant. Serum TC, TG, HDL, LD, and VLDL level decreased more in Child-Turcotte-Pough Criteria (CTP) Class C as compared to CTP Class B. The TC, HDL, and LDL belonged cases to the CTP class C and B showed (P&lt;0.05) found statistical significance, which can be further correlated with the severity of cirrhosis. In the present study, the level of TG and VLDL was (P&gt;0.05) found statistically non-significant. Conclusion: All the lipid parameters decrease in cirrhotic patients as compare to non-cirrhotic subjects and progressively lower the parameters as severity of liver disease increased.

Study of serum lipid profile in patients with chronic liver disease and its correlation with child Pugh class: a hospital based observational study in North Indian patients

Background: Liver disease impacts on hepatic synthesis of lipoproteins and lipogenesis but data on dyslipidemia during disease progression are limited. We want assess the patterns of dyslipidemia in with different etiology liver disease and its correlation with Child Pugh score from non-advanced (non-ACLD) advanced chronic liver disease (ACLD) as it is unclear how progression to ACLD impacts on dyslipidemia-associated cardiovascular risk. Aim and objectives of current study were to determine serum lipid profile in patients with chronic liver disease and its correlation with Child Pugh score. Methods: It was Cross sectional, observational study conducted in 200 patients at KPS post graduate institute of medicine, GSVM medical college, Kanpur from December 2020 to October 2022. Results: In this study mean value of Serum Cholesterol (mg/dl) was 135.25 (27.88), Serum Triglycerides (mg/dl) was 122.27 (36.29), HDL Cholesterol was 46.92 (10.36), LDL Cholesterol was 62.77 (22.59), VLDL Cholesterol was 25.62 (8.71). In this study maximum patients of chronic liver disease were due to chronic alcohol intake which account for 76% patients, 2nd most common aetiology of chronic liver disease were chronic viral hepatitis and rest were due to Wilson disease, Budd Chiari syndrome non cirrhotic portal fibrosis and cryptogenic. Patients of chronic liver disease have negative correlation on lipid profile with Child Pugh score. Conclusions: From our study its was concluded that patients having higher CTP score having more derangement (low) in serum lipid profile (specially) serum cholesterol, serum HDL, serum VLDL) than the patients having low CTP score.

Effectiveness of atorvastatin on the levels of nitric oxide and serum lipids in coronary artery disease patients: Response to clopidogrel resistance

Introduction and aim: Lipid lower drugs have been widely used to prevent atherosclerosis in patients with heart disease. This study aims to compare the findings between the efficacy of 20 mg/day and 40 mg/day atorvastatin supplementation for 16 weeks, on nitric oxide level and lipid profile in clopidogrel resistant and non-resistant patients with coronary heart disease (CAD). Methods: This retrospective study included two hundred and eighty-four participants with CAD. Patients were subjected to platelets function to determine the clopidogrel resistance. 88 patients were included into the clopidogrel resistant group, and 196 patients were included into the clopidogrel non-resistant group. Each group was subdivided into two subgroups depending on the daily dose of atorvastatin therapy (daily intake of 20 mg and 40 mg, orally). Results: Irrelevant to the study group, there was significant increase in serum levels of NO following 40 mg/day clopidogrel supplementation for 16 weeks as compared to 20 mg/day clopidogrel supplementation, P ≤ 0.05. This was associated with a significant reduction in serum lipids (total cholesterol and LDL-C), P ≤ 0.05. Conclusion: Atorvastatin supplementation improves serum nitric oxide level, and serum lipid profile in patients with CAD with and without clopidogrel resistance.

Effect of fenugreek (Trigonella foenum-graecum) seed powder on lipid profile: A single blind placebo controlled study

Background: Dyslipidemia is one of the most prevalent risk factors contributing to atherosclerotic cardiovascular disease. Clinical trials have demonstrated that treatment of dyslipidemia reduces cardiovascular events. Fenugreek seed powder supplementation has lipid-lowering activity, but has not been studied extensively. In light of this, we undertook the present study at tertiary care hospital in Amravati, Maharashtra, with the aim of studying the effect of fenugreek seed powder on serum lipid profile in patients with dyslipidemia &amp; to determine the adverse effects of it. Methods: The study was a single blind placebo controlled study conducted on 60 patients with dyslipidemia from June 2022 to November 2022, after meeting inclusion and exclusion criteria. Results: It was found significant decrease in serum total cholesterol (237.32 to 204.51mg/dl) p value &lt;0.001, serum LDL cholesterol (154.69 to 133.88 mg/dl) p value &lt; 0.001 &amp; serum triglycerides (196.95 to 165.09 mg/dl) p &lt;0.01 with no effect on serum HDL cholesterol (41.11 to 38.92mg/dl) p &gt;0.05, without any major side effects. Conclusion: Fenugreek seed powder significantly lowers serum total cholesterol, LDL cholesterol and triglyceride levels in dyslipidemia patients, with no effect on serum HDL cholesterol levels. fenugreek seed powder supplementation considerably improves lipid Profile. Hence it could be well-thought-out as an effective lipid lowering nutritional supplement. Further high quality &amp; large scale studies are needed to decisively establish the clinical efficacy of fenugreek seed powder. Keywords: fenugreek seed powder; dyslipidemia; lipid profile; cholesterol; LDL; triglycerides; HDL

Significance of Serum Ferritin and Vitamin-D Level in Coronary Artery Disease Patients

Introduction: Coronary artery disease is one of the most common noncommunicable diseases that affects both men and women worldwide. Chronic inflammation and mineral nutrient deficiency, in addition to diet and sedentary lifestyle, contribute to this disease. The purpose of this study is to look at the relationship between serum ferritin, serum vitamin D levels, and serum lipid profile in patients with Coronary Artery Disease. Methods: The research was carried out at the Mahatma Gandhi Medical College and Research Institute in Puducherry. A standardised health questionnaire was distributed to study participants, which included 30 patients with Coronary Artery Disease (cases) and 30 healthy controls. It detailed current and previous medication use, hypertension, and coronary artery disease. Subjects were chosen based on their responses to study-related questions. For both cases and controls, means and standard deviations (SD) were computed. To determine the relationship between the parameters, ANOVA and Pearson's correlation were used, and it was used to find the statistical significance and correlation of Serum Ferritin, Serum Vitamin D, and Serum Lipid Profile among both groups. Results: The serum ferritin levels among cases (208.87±143.01 µg/lit) were found to be high when compared to controls (99.52 ± 61.19 µg/lit) with a significant p value of 0.0003. The Serum vitamin D value of cases (21.14 ± 12.9 ng/dl) was low when compared to controls (56.54 ± 18.88 ng/dl) with a significant p value of 0.0000. Serum LDL of cases (129.1 ± 26.91 mg/dl) were found to be higher than controls (105.1 ± 25.43 mg/dl). HDL of cases (33.83±6.82mg/dl) was found to be lower than controls (49.53±6.12 mg/dl). Conclusion: Altered lipid profile with low HDL-C, high LDL-C, and high LDL-C/HDL-C suggested an increased risk for CAD. Low vitamin D levels were also associated with a higher risk for CAD. According to this study, CAD patients had high serum ferritin levels, low serum vitamin D levels, and an altered lipid profile status.

Serum lipid profile in patients with ischaemic stroke the - correlation between them

Serum lipid profile in patients with ischaemic stroke the - correlation between them

Serum Lipid Profiles in Patients with Systemic Lupus Erythematosus

1. Background: Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple organ systems. Lipid profile is a panel of blood test that serves as an initial broad medical screening tool for abnormalities in lipid such as cholesterol and triacylglycerol. The result of this test can identify certain genetic diseases and can determine approximate risk for cardiovascular diseases, cerebrovascular diseases and certain form of pancreatitis and other diseases. Premature cardiovascular disease is the leading cause of morbidity in lupus which may be directly associated with altered lipid metabolism in systemic lupus erythematosus patient. Objective: To find out the relation of serum lipid profile with systemic lupus erythematosus patients. Methodology: This cross sectional study was conducted in the Department of Biochemistry, Dhaka Medical College, Dhaka from January 2017 to December 2017. In this study, fifty diagnosed patients of SLE (Group A) and fifty apparently healthy individuals (Group B) of both sexes were selected according to the selection criteria from Department of Medicine, Dhaka medical college hospital, Dhaka (Group A) and by personal contact (Group B). Baseline parameters (body mass index, blood pressure and fasting plasma glucose) of both groups were measured. Serum lipid profile was estimated by enzyme immune assay, total cholesterol (TC), triglyceride (TG) and high density cholesterol (HDL-c) was estimated by enzymatic method. Results: Among the parameters of lipid profile serum TC, TG and LDL-C were significantly higher (p &lt;0.001) in SLE patients than that of healthy individuals and serum HDL-C concentration was lower in SLE group than healthy group which highly significant. Correlation of SLE with serum TC, TG, LDL-C was significantly positive (p &lt;0.001) and with HDL-c there was an inverse correlation which was significant (p&lt;0.001). Conclusion: Serum lipid profile was significantly dysregulated in SLE patients. Moreover, .........

Paraoxonase 1 rs662 polymorphism, its related variables, and COVID-19 intensity: Considering gender and post-COVID complications.

In this study, we aimed to investigate the effect of paraoxonase 1 (PON1) rs662 polymorphism, arylesterase (ARE) activity, and the serum lipid profile in patients with coronavirus disease 2019 (COVID-19) in different stages of the disease considering post-COVID outcomes. A total of 470 COVID-19 patients (235 female and 235 male patients) were recruited into the study, and based on the World Health Organization (WHO) criteria, the patients were divided into three groups: moderate, severe, and critical. PON1 rs662 polymorphism was determined by the Alw 1 enzyme followed by agarose gel electrophoresis. Moreover, serum levels of triglycerides (TG), cholesterol (Chol), high-density lipoprotein-cholesterol (HDL-c), and low-density lipoprotein-cholesterol (LDL-c), as well as the level of the ARE activity of PON1 in the sera of patients were measured at the time of infection and one and three months after hospitalization. There was a significant relationship between the G allele and the severity of the disease. In addition, the probability of death in homozygous individuals (GG) was higher than in heterozygous patients (GA), and it was higher in heterozygous patients than in wild-type individuals (AA). There was also a significant relationship between the decrease in serum lipids and the intensity of COVID-19. On the contrary, at the onset of the disease, the HDL-c level and serum ARE activity were reduced compared to one and three months after COVID-19 infection. The findings of this study indicated the significant impact of PON1 rs662 polymorphism on ARE activity, lipid profiles, disease severity, and mortality in COVID-19 patients.

Assessment of serum lipid profile in patients with oral potentially malignant disorders

Background: To assess the serum lipid profile in oral potentially malignant disorder patients. Materials & methods: A total of 40 subjects were enrolled. Age of the patients was 40 to 70 years. 20 clinically diagnosed with oral potentially malignant disorders were included in this study. 20 healthy individuals, who had no complaint or any major illness in the recent past, were included in the study as controls. Laboratory investigations were done. Blood samples were collected. Plasma levels of cholesterol, triglycerides, and HDL were calculated. Result was analysed using SPSS software. Results: In group I, the triglycerides level was 135.62 mg/dl and in group II, the triglycerides level was 195.3 mg/dl. A statistically significant P < 0.001, decrease in mean plasma triglyceride level is observed in the oral potentially malignant disorder (OPMD) group as compared with the control group. In group I, levels of HDL, LDL and VLDL were 50.62 mg/dl, 90.36 mg/dl and 22.63 mg/dl whereas in control group the levels were 74.82 mg/dl, 108.46 mg/dl and 34.66 mg/dl respectively. Statistically significant P < 0.001 decrease of plasma LDL levels is observed in the oral potentially malignant disorder as compared to the control group. Conclusion: The change in lipid levels can have a diagnostic role in oral potentially malignant disorder patients.

A Comparative Study of Serum Lipid Profile in Patients with Oral Squamous Cell Carcinoma and Healthy Population in a Tertiary Health Care Centre in North-Western India

Aims and Objectives: The aim of the study was to study serum lipid profile in patients with oral squamous cell carcinoma (OSCC) and to compare their levels with those of healthy population. Materials and Methods: This study was done in forty five patients of Oral Squamous Cell Carcinoma and the results were compared with results of forty five age and sex matched healthy controls . Serum obtained from centrifugation of 12 hour fasting blood samples was analyzed on fully automated analyzer Beckman coulter AU-680 for estimating the lipid levels (cholesterol, triglycerides [TGL], and high-density lipids [HDL]) by colorimetric method. Low-density lipid [LDL] values were obtained by calculator. Results: The comparison of lipid profile levels between Oral Squamous Cell Carcinoma cases and healthy controls shows statistically significant results for TC, HDL and LDL. Conclusion: The change in lipid levels may have an early diagnostic or prognostic role in oral malignant lesions and can be used as a biomarker for OSCC patients.

The effect of Allium hirtifolium bulb on serum lipid profile in adult patients with hyperlipidemia: A randomized double-blind placebo-controlled clinical trial

BackgroundOne of the first goals of reducing the risk of cardiovascular disease (CVD) is to achieve effective therapies for hyperlipidemia. This study aimed to investigate the effect of Allium hirtifolium bulbs on serum lipid profile in patients with hyperlipidemia. MethodsThis clinical trial was conducted on hyperlipidemic patients in two drug (Allium; n = 25) and placebo (n = 24) groups. The first group received 500 mg of A. hirtifolium bulbs twice daily for 6 weeks, while the second group received placebo for the same frequency and duration. Cholesterol, triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), fasting blood sugar (FBS), creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured at the beginning and the end of study and were compared between the groups. ResultsA. hirtifolium reduced total cholesterol and LDL significantly compared to the placebo (P < 0.05). However, no significant effects on other parameters were observed. Furthermore, the use of A. hirtifolium had no effects on renal and liver function tests. ConclusionThe use of A. hirtifolium bulbs can decrease serum total cholesterol and LDL in hyperlipidemic adult patients.

Effects of alpha lipoic acid supplementation on serum lipid profile in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial.

Alpha lipoic acid (ALA) is considered a strong antioxidant with anti-inflammatory properties. Moreover, a number of previous studies have shown its lipid-lowering properties. Therefore, we designed this study to investigate the effects of ALA on lipid profile in patients with metabolic syndrome (MetS), which can lead to an increased risk of cardiovascular disease (CVD) and premature mortality. A total 46 patients with MetS were randomly divided into two groups. They received either 600 mg ALA (n = 23) or 600 mg placebo (n = 23) for 12 weeks. The body weight, height, body mass index (BMI), waist circumference (WC), fasting blood sugar (FBS), hemoglobin A1C (HbA1c), and blood pressure (BP) were assessed at baseline of the study. Physical activity level and dietary intake were assessed at baseline and end of the study. Serum lipid profile including triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC) were measured before and after 12 weeks of intervention. Baseline characteristics were similar in the ALA and placebo groups (P > 0.05). However, there were statistically significant differences in plasma levels of TG (-36.82 ± 42.48 versus 6.15 ± 25.04 mg/dl, P = 0.001) and TC (-8.91 ± 20.65 versus 10.84 ± 22.97 mg/dl, P = 0.01) after 12 weeks between the ALA group and the placebo group. Yet, there were no statistically significant differences in plasma levels of HDL-C and LDL-C after 12 weeks between the ALA group and the placebo group. The results suggest that daily supplementation of 600 mg ALA for 12 weeks may improve the lipid profile in patients with MetS.